Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study

UnknownOBSERVATIONAL
Enrollment

12

Participants

Timeline

Start Date

June 10, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Acute Myelogenous Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)Non Hodgkin Lymphoma (NHL)Hodgkin Lymphoma, Adult
Interventions
OTHER

non intervational

Subjects who completed ApoGraft-01 study (through 180 days post-transplantation) and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend 4 in-clinic visits, once every 6 months up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence)

Trial Locations (1)

Unknown

RECRUITING

Rambam Medical Center, Haifa

Sponsors
All Listed Sponsors
lead

Cellect Biotechnology

INDUSTRY